tiprankstipranks
Oruka Therapeutics (ORKA)
NASDAQ:ORKA
Holding ORKA?
Track your performance easily

Oruka Therapeutics (ORKA) Income Statement

593 Followers

Oruka Therapeutics Income Statement

Last quarter (Q2 2024), Oruka Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Oruka Therapeutics's net income was $-2.68M. See Oruka Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 9.13M$ 7.30M$ 10.60M$ 19.34M$ 9.77M$ 5.81M
Operating Income
$ -9.13M$ -7.30M$ -10.60M$ -19.34M$ -9.77M$ -5.81M
Net Non Operating Interest Income Expense
$ 1.93M$ 1.96M$ 675.00K$ 13.00K$ 19.00K$ 165.00K
Other Income Expense
--$ -5.00K---
Pretax Income
$ -7.20M$ -5.34M$ -9.93M$ -19.32M$ -9.75M$ -5.65M
Tax Provision
$ -192.00K$ -192.00K$ -357.00K$ -695.00K$ -9.00K$ -167.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -7.20M$ -5.34M$ -9.93M$ -19.32M$ -9.74M$ -5.48M
Basic EPS
$ -0.50$ -0.37$ -8.28$ -16.68$ -24.84-
Diluted EPS
$ -0.50$ -0.37$ -8.28$ -16.68$ -24.84$ -49.80
Basic Average Shares
$ 57.85M$ 14.42M$ 1.20M$ 1.16M$ 392.52K$ 110.10K
Diluted Average Shares
$ 57.85M$ 14.42M$ 1.20M$ 1.16M$ 392.52K$ 110.10K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 9.13M$ 7.30M$ 10.60M$ 19.34M$ 9.77M$ 5.81M
Net Income From Continuing And Discontinued Operation
$ -7.20M$ -5.34M$ -9.93M$ -19.32M$ -9.74M$ -5.48M
Normalized Income
$ -5.92M$ -5.37M----
Interest Expense
------
EBIT
$ -7.91M$ -5.53M$ -10.60M$ -19.34M$ -9.74M$ -5.64M
EBITDA
$ -7.82M$ -5.42M$ -10.48M$ -19.24M$ -9.64M$ -5.55M
Currency in USD

Oruka Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis